Personalis Reports Strong Q1 Growth in Genomics

Personalis ( (PSNL) ) has released its Q1 earnings. Here is a breakdown of the information Personalis presented to its investors.

Personalis, Inc., based in Fremont, California, is a leader in advanced genomics for precision oncology, focusing on personalized cancer management through innovative testing solutions. In the first quarter of 2025, Personalis reported significant growth in clinical test volumes and a notable increase in revenue from pharma tests and services, highlighting the growing adoption of its technology. The company delivered 2,184 molecular tests, marking a 52% increase from the previous quarter, and achieved a 39% year-over-year revenue growth in pharma tests and services.

Key financial metrics for the first quarter of 2025 include a total revenue of $20.6 million, a 6% increase from the previous year, driven by the rise in pharma tests and services. However, the company reported a net loss of $15.8 million, with a net loss per share of $0.18. Despite the loss, Personalis improved its gross margin to 35% from 28.1% the previous year, attributed to a favorable revenue mix.

Strategically, Personalis made significant strides with its NeXT Personal platform, demonstrating its effectiveness in detecting colorectal cancer recurrences and publishing pivotal studies in breast and lung cancer. These advancements underscore the company’s commitment to enhancing cancer detection and management.

Looking ahead, Personalis maintains a positive outlook, expecting total revenue for 2025 to range between $80 to $90 million, with continued growth in pharma tests and services. The company plans to invest in expanding clinical studies and commercial capabilities, aiming to drive further growth and achieve Medicare reimbursement for its breast cancer tests by the end of the year.